Company intelligence / Profile preview

Prothione

Franklin, Tennessee, United Statespmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Phase 2

Overview

Prothione LLC has developed a pro-glutathione therapy in capsule form that demonstrated positive results in a Phase II clinical trial for mild to moderate COVID‑19. The trial showed statistically significant reductions in viral load and time to clinical resolution compared to placebo. The product was safe and well-tolerated. An over-the-counter version called Immune Formulation 200® (IF200) has been approved by the Rwanda FDA and is available for sale in the US[1][3].

Therapeutic areas: ImmunologyInfectious Diseases
Modalities: Small molecule (amino acid-based therapy)Nutraceutical
Industry: Biotech

Drug pipeline

1 asset

Prothione

Partnerships

Planning collaborations for Phase III trials; no major pharma partnerships disclosed[3]

Beyond the preview

Go deeper on Prothione.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Prothione.

Explore the full profile